Search Results
Your search for ,WHo matches 20376 pages
Showing 9351 - 9400Capsaicin
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Shelly Latte-Naor, MD, and Jyothirmai Gubili, MS, explore the use of...
Francoise Mornex, MD, PhD, Named First Female Recipient of Heine H. Hansen Award
The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) recently awarded the 2019 Heine H. Hansen Award to Francoise Mornex, MD, PhD. The award was presented at the 2019 European Lung Cancer Congress. Dr. Mornex is Professor of...
Ghanaian Oncologist Yehoda M. Martei, MD, Seeks Ways to Improve Outcomes in the Developing World
Breast cancer remains the most commonly diagnosed cancer among women globally. Due to a lack of early interventions, most women in low- and middle-income countries have advanced disease at the time of diagnosis, conferring a grim prognosis. Yehoda M. Martei, MD, of the Department of Medicine,...
Measuring the Burden of Global Cancer as a Tool for Policymakers
The Global Burden of Disease Study was initiated in 1990, commissioned by the World Bank. At that time, the study was conducted mainly by researchers at Harvard and the World Health Organization (WHO). Since then the study has gone through many iterations to its present structure, which is a...
NIH Selects Three Oncology Investigators as Lasker Clinical Research Scholars
The National Institutes of Health (NIH) has selected eight scientists as Lasker Clinical Research Scholars as part of a joint initiative with the Albert and Mary Lasker Foundation to foster the next generation of clinical scientists. This program provides early-stage researchers with the...
Uniting the Global Cancer Community to Reduce Deaths From Noncommunicable Diseases
It has been well documented that noncommunicable diseases, including cancer, cardiovascular disease, and diabetes, now pose the greatest health threat to people living in low- and middle-income countries, surpassing infectious diseases like HIV/AIDS as the leading cause of death and disability.1...
Pat A. Basu, MD, MBA, Named President and Chief Executive Officer of Cancer Treatment Centers of America
Pat A. Basu, MD, MBA, has been appointed President and Chief Executive Officer of Cancer Treatment Centers of America Global, Inc., which includes the existing Comprehensive Cancer Care Network of Cancer Treatment Centers of America® (CTCA) hospitals and outpatient care centers, as well as new...
AACR Honors Elaine Fuchs, PhD, With 2019 AACR G.H.A. Clowes Memorial Award
The American Association for Cancer Research (AACR) has awarded the 59th AACR G.H.A. Clowes Memorial Award to Elaine Fuchs, PhD. The award was presented during the AACR Annual Meeting 2019. Dr. Fuchs delivered her award lecture, “Stem Cells in Wound Repair, Inflammation, and Cancer,” at the Georgia ...
ASH President Comments on Medicare Proposal for CAR T-Cell Therapy
Recently, the Centers for Medicare & Medicaid Services (CMS) proposed to improve the reimbursement currently given to hospitals that provide chimeric antigen receptor (CAR) T-cell therapy to patients with blood cancer as part of the Fiscal Year 2020 Inpatient Prospective Payment System...
St. Jude Children’s Research Hospital and WHO Join Forces to Improve Childhood Cancer Survival Worldwide
A report by the International Agency for Research on Cancer (IARC) based on data from more than 100 cancer registries in 68 countries shows that from 2001 to 2010, the occurrence of childhood cancer worldwide was 13% more common than in the 1980s.1 In addition, the report’s findings showcase stark...
Teen Cancer America Announces New Advisory Council
Teen Cancer America (TCA), the national nonprofit organization founded by rock artists Roger Daltrey and Pete Townshend of The Who, recently announced appointments to its newly formed Advisory Council. Based in Los Angeles, TCA develops specialized facilities as well as treatment- and age-specific...
How Cancer Affects Adolescents and Young Adults
The statistics are alarming: according to the National Cancer Institute (NCI), about 70,000 adolescents and young adults (AYAs) are diagnosed with cancer each year1—a recent report by the University of California put that figure at 87,000.2 Although overall cancer survival rates continue to improve ...
New Radiation Options for Localized Prostate Cancer May Improve Patient Outcomes
External-beam radiation therapy (EBRT) is a standard treatment option for men with localized prostate cancer and confers long-term prostate cancer control outcomes equal to radical prostatectomy. Technologic advances in imaging and computing during the past 20 years have led to a number of...
NCCN Roundtable Tackles Issues With Innovative Immunotherapies
Immunotherapies are radically changing outcomes, but while helping patients, they are creating complexities surrounding their cost. At the 2019 Annual Conference of the National Comprehensive Cancer Network® (NCCN®), a roundtable of experts, including clinicians and payers, discussed how chimeric...
Erdafitinib for Metastatic Urothelial Carcinoma
On April 12, 2019, erdafitinib was granted accelerated approval for patients with locally advanced or metastatic urothelial carcinoma with susceptible fibroblast growth factor receptor 3 (FGFR3) or FGFR2 genetic alterations, when the disease has progressed during or following platinum-containing...
FDA Approves Chemotherapy-Free Regimen, Venetoclax Plus Obinutuzumab, as First-Line Treatment for CLL/SLL
On May 15, the U.S. Food and Drug Administration (FDA) approved venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Approval was based on the CLL14...
FDA Expands Pembrolizumab Indication for NSCLC in First-Line Setting
On April 14, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the first-line treatment of patients with stage III non–small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation, or those with metastatic NSCLC....
AIM at Melanoma Foundation Opens First Melanoma Tissue Bank in the United States
The AIM at Melanoma Foundation recently announced the grand opening of the first branch of the International Melanoma Tissue Bank Consortium (IMTBC) at the Hillman Cancer Center, University of Pittsburgh Medical Center (UPMC). The Pittsburgh site is the first of six global locations of the...
FDA Approves First-Line Ivosidenib for IDH1-Mutated AML
On May 2, the U.S. Food and Drug Administration (FDA) expanded its approval of ivosidenib (Tibsovo) to include newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that ...
Combination Immunotherapy With Lenalidomide Plus Rituximab in Indolent NHL: Time to Replace Rituximab Monotherapy?
With increasing knowledge on the key role of the tumor microenvironment in lymphomagenesis, treatments for indolent B-cell lymphoma, especially follicular lymphoma, are mechanistically moving toward a more immunomodulatory approach. Chemotherapy-free regimens are an attractive alternative to...
Dana-Farber Opens New Center for Patients With Lynch Syndrome
Dana-Farber Cancer Institute recently announced the opening of the first Lynch Syndrome Center dedicated to providing genetic counseling and testing for those at risk for the syndrome and delivering a new model of coordinated care for those living with the disease. A common and underdiagnosed...
Jonas Bergh, MD, PhD, FRCP, Receives First ESMO Breast Cancer Award
The European Society for Medical Oncology (ESMO) announced recently that Jonas Bergh, MD, PhD, FRCP, of the Karolinska Institutet in Stockholm, has been awarded the newly established 2019 ESMO Breast Cancer Award at the inaugural ESMO Breast Cancer Congress 2019. The ESMO Breast Cancer Award...
AUGMENT Trial: Addition of Lenalidomide to Rituximab in Relapsed or Refractory Indolent Lymphoma
In the phase III AUGMENT trial, reported in the Journal of Clinical Oncology, John P. Leonard, MD, of Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, and colleagues found that the addition of lenalidomide to rituximab significantly prolonged progression-free survival...
City of Hope Announces Faculty Awards
Over the past year, in recognition of their research and dedication to treating patients with cancer, several physician-scientists from City of Hope received awards, fellowships, and honor society inductions. These recipients listed below are experts in a variety of cancers and treatments, ranging...
2019 NCCN Posters Explore Next-Generation Sequencing, Cancer Burden vs Funding, Cardiac Monitoring, and Scalp Cooling
Posters presented at the National Comprehensive Cancer Network® (NCCN®) Annual Conference continue to grow in number and in quality. The ASCO Post presents a few that we found interesting at the recent 2019 meeting. Next-Generation Sequencing Not Always Helpful in Practice The value of...
Prolonged Exposure to Ibrutinib May Increase Effectiveness of CAR T-Cell Therapy in Patients With CLL
Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable efficacy in the treatment of certain hematologic malignancies, including several types of large B-cell non-Hodgkin lymphomas (NHLs) and acute lymphoblastic leukemia (ALL). The U.S. Food and Drug Administration (FDA) has approved...
Introducing CancerLinQ® 2.0 and a New Era in Precision Oncology
In just 5 years since its launch in 2014, CancerLinQ®, ASCO’s big-data, rapid-learning, health information technology platform, has grown from 37 vanguard oncology practices to 58 participating practices in 2016 to 100 diverse oncology practices nationwide this year. CancerLinQ...
Prostate-Only vs Whole-Pelvis Radiotherapy in Gleason Grade 5 Prostate Cancer
In a retrospective analysis published in European Urology, Sandler et al examined the protocol for treating aggressive prostate cancer. Researchers aimed to study the impact of whole-pelvis radiation on men with Gleason grade 5 disease who had been treated with external-beam radiotherapy with...
Factors Associated With Major Adverse Cardiovascular Events in Survivors of Colorectal Cancer
Colorectal cancer survivors’ risk for heart attack—five times that of the average person—may be linked to the amount of fat stored within the abdomen and abdominal muscles, not to body mass index (BMI), according to a new study of 2,800 colon cancer survivor health outcomes...
OPTIMISMM: Addition of Pomalidomide to Bortezomib/Dexamethasone in Pretreated Relapsed or Refractory Multiple Myeloma
In the phase III OPTIMISMM trial, reported by Richardson et al in The Lancet Oncology, researchers found that the addition of pomalidomide to bortezomib/dexamethasone improved progression-free survival in relapsed or refractory multiple myeloma previously treated with lenalidomide. Study Details...
Members of Congress Express Support for Cancer Policy Priorities During Capitol Hill Event
ASCO and the American Cancer Society Cancer Action Network (ACS CAN) hosted a reception on Capitol Hill for Members of Congress and their staff to underscore the two organizations’ shared policy priorities to improve research and cancer care delivery for patients and survivors. During the...
ASCO Announces New Task Force to Address Rural Cancer Care Gap
ASCO recently announced a new task force aimed at reducing disparities and improving outcomes for patients and survivors of cancer who live in rural communities. The new Rural Cancer Care Task Force will identify opportunities to close the rural cancer care gap and implement strategies to improve...
Researchers Supported by Conquer Cancer, the ASCO Foundation, Earn Spot in Clinical Cancer Advances 2019
The work of nine researchers who have previously received funding from Conquer Cancer is featured in ASCO’s Clinical Cancer Advances 2019. Visit CONQUER.ORG/CCA for more details. In two separate trials, Conquer Cancer–supported investigators produced research results that improved treatment for...
Access ASCO’s Quality Programs to Accelerate Quality Care Delivery in Your Practice
Improve the care your practice provides by participating in ASCO’s wide array of quality improvement programs. ASCO’s Quality Oncology Practice Initiative (QOPI®) is an oncologist-led, practice-based quality assessment program designed to promote excellence in cancer care by helping practices...
Mary Beckerle, PhD, and Martin McMahon, PhD, Appointed to National Scientific Leadership Roles
Mary Beckerle, PhD, Chief Executive Officer at Huntsman Cancer Institute and Professor of Biology and Oncological Sciences, University of Utah, and Martin McMahon, PhD, Huntsman Cancer Institute’s Senior Director of Pre-Clinical Translation and Professor of Dermatology, have been appointed to...
IMPACT Study, Aimed at Increasing Diversity Among Clinical Trial Participants, Launches
The University of Southern California (USC) Norris Comprehensive Cancer Center has launched a study to determine how financial assistance for costs associated with clinical trial participation might increase enrollment, particularly among low-income patients and racial and ethnic minorities. The...
Expert Point of View: Marcie L. Riches, MD, MS
Marcie L. Riches, MD, MS, Director of Clinical Research and Data Quality and Bone Marrow Transplant Clinic Medical Director, and Clinical Associate Chief of Hematology/Oncology at the University of North Carolina at Chapel Hill, commented on the study of tabelecleucel for The ASCO Post. At the...
T-Cell Therapy for EBV-Associated Posttransplant Lymphoproliferative Disorder With CNS Involvement
An “off-the-shelf” allogeneic T-cell product, tabelecleucel, may effectively treat patients who develop Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disorder with central nervous system (CNS) involvement, researchers from Memorial Sloan Kettering Cancer Center reported at...
ASCO Guideline Recommends Shorter-Course Adjuvant Chemotherapy for Some Patients With Stage III Colon Cancer
In a clinical practice guideline released April 15, an ASCO Expert Panel outlined the latest recommendations for the duration of adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin for patients with completely resected stage III colon cancer.1 New recommendations were based on the results ...
Erythropoiesis-Stimulating Agents Recommended for Some Patients With Cancer and Anemia
ASCO and the American Society of Hematology (ASH) have released an update to existing guidelines for use of erythropoiesis-stimulating agents to manage anemia in patients with cancer.1 “The current update aims to increase awareness of recent developments regarding the use of...
Early-Stage Study of Nivolumab Alone or in Combination With Cisplatin/Gemcitabine in Biliary Tract Cancer
In a Japanese phase I trial reported by Ueno et al in The Lancet Gastroenterology & Hepatology, researchers found nivolumab showed activity and had a manageable safety profile in patients with unresectable or recurrent biliary tract cancer. Methods The open-label phase I trial was conducted...
Expert Point of View: Julie Margenthaler, MD, FACS
Julie Margenthaler, MD, FACS, Professor of Surgery at Washington University School of Medicine and a breast surgeon at Siteman Cancer Center, St. Louis, underscored the “overall excellent outcomes” being achieved with chemotherapy and HER2-targeted therapy for patients with HER2-positive breast...
Study Finds Timing of Therapy Does Not Influence Outcomes in HER2-Positive Breast Cancer
The sequencing of trastuzumab administration with chemotherapy in the neoadjuvant setting seems to have no effect on outcomes for patients with HER2-positive breast cancer, according to data presented at the 2019 Society of Surgical Oncology Annual Cancer Symposium.1 The results of a phase III...
Susan G. Komen Welcomes Five Leaders to New Research Advisory Roles
Susan G. Komen recently announced new organizational advisory roles for five breast cancer oncologists. The new appointees will join the group of breast cancer researchers, clinicians, and advocates who help guide the organization’s work, particularly through the organization’s $988 million...
Trastuzumab Emtansine in Treatment of Residual Breast Cancer After Neoadjuvant Therapy: Who Will Benefit?
The discovery of trastuzumab has been revolutionary in the treatment of HER2-positive breast cancer, both in the metastatic and early-stage settings.1-6 This cannot be disputed. In the early-stage setting, the addition of trastuzumab to standard chemotherapy has led to a 50% gain in...
Adjuvant Trastuzumab Emtansine vs Standard Trastuzumab in Residual HER2-Positive Breast Cancer After Neoadjuvant Therapy
In the phase III KATHERINE trial reported in The New England Journal of Medicine,1Gunter von Minckwitz, MD, of the German Breast Group, Neu-Isenburg, and colleagues found that adjuvant treatment with the antibody-drug conjugate trastuzumab emtansine (T-DM1) improved invasive disease–free survival...
ACCURE Trial: Improving Racial Disparities in Treatment for Patients With Early-Stage Lung and Breast Cancers
Results from a study published by Cykert et al in The Journal of the National Medical Association show that a pragmatic system-based intervention within cancer treatment centers can nearly eliminate existing disparities in treatment and outcomes for black patients with early-stage...
FDA Approves T-DM1 for HER2-Positive Early Breast Cancer
On May 3, the U.S. Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (T-DM1; Kadcyla) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane- and trastuzumab-based treatment. Patients should be...
Alterations in the RB1 Gene and Outcomes in Metastatic Castration-Resistant Prostate Cancer
Scientists have identified a genetic mutation in the tumors of some men with prostate cancer that is linked to very poor survival, and which could be used to help select certain patients for more intensive treatment. These findings were published by Abida et al in the Proceedings of the...
Expert Point of View: David Gandara, MD
“MYSTIC is the second phase III trial to compare a first-line immune checkpoint inhibitor with platinum that failed to meet the primary endpoint. However, both MYSTIC and CheckMate 026 identified patients who benefited from an immune checkpoint inhibitor based on tumor mutational burden,”...
